PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 83 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $323,184 | -15.6% | 122,892 | +13.3% | 0.01% | -20.0% |
| Q2 2023 | $382,801 | +23.8% | 108,448 | +8.4% | 0.02% | +15.4% |
| Q1 2023 | $309,204 | -17.2% | 100,072 | +13.3% | 0.01% | -31.6% |
| Q4 2022 | $373,602 | +91.6% | 88,322 | +7.4% | 0.02% | +90.0% |
| Q3 2022 | $195,000 | -6.7% | 82,247 | +12.0% | 0.01% | -9.1% |
| Q2 2022 | $209,000 | +21.5% | 73,424 | +23.0% | 0.01% | +57.1% |
| Q1 2022 | $172,000 | +56.4% | 59,680 | +65.6% | 0.01% | +40.0% |
| Q4 2021 | $110,000 | -55.6% | 36,032 | +1.9% | 0.01% | -58.3% |
| Q3 2021 | $248,000 | +5.1% | 35,360 | +37.3% | 0.01% | 0.0% |
| Q2 2021 | $236,000 | +11.3% | 25,745 | +18.3% | 0.01% | -7.7% |
| Q1 2021 | $212,000 | +9.8% | 21,768 | +15.6% | 0.01% | 0.0% |
| Q4 2020 | $193,000 | +52.0% | 18,828 | +54.5% | 0.01% | +18.2% |
| Q2 2020 | $127,000 | – | 12,186 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |